Financhill
Sell
34

TOI Quote, Financials, Valuation and Earnings

Last price:
$0.31
Seasonality move :
-29.03%
Day range:
$0.29 - $0.33
52-week range:
$0.13 - $2.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.06x
P/B ratio:
1.46x
Volume:
257.4K
Avg. volume:
2.1M
1-year change:
-84.35%
Market cap:
$22.6M
Revenue:
$324.2M
EPS (TTM):
-$0.78

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Upside
    No price target exists because of limited analyst coverage.
  • Price Target Downside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, The Oncology Institute has 569.12% upside to fair value with a price target of -- per share.

TOI vs. S&P 500

  • Over the past 5 trading days, The Oncology Institute has underperformed the S&P 500 by -2.87% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • The Oncology Institute does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • The Oncology Institute has grown year-over-year revenues for 11 quarters straight. In the most recent quarter The Oncology Institute reported revenues of $99.9M.

Earnings Growth

  • The Oncology Institute has grown year-over-year earnings for 0 quarters straight. In the most recent quarter The Oncology Institute reported earnings per share of -$0.18.
Enterprise value:
66.7M
EV / Invested capital:
--
Price / LTM sales:
0.06x
EV / EBIT:
--
EV / Revenue:
0.18x
PEG ratio (5yr expected):
-0.10x
EV / Free cash flow:
-1.78x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$53.7M
Return On Assets:
-35.44%
Net Income Margin (TTM):
-18.54%
Return On Equity:
-163.45%
Return On Invested Capital:
-53.47%
Operating Margin:
-13.87%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $233.4M $309.9M $378.9M $82M $99.9M
Gross Profit $44.8M $60.8M $53.7M $16M $14.4M
Operating Income -$97.7M -$60M -$63.5M -$13.9M -$13.9M
EBITDA $4.5M -$62.6M -$56.1M -$13.8M -$12.3M
Diluted EPS -$0.17 -$0.86 -$0.78 -$0.19 -$0.18
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets -- -- $143.6M $152.7M $116.4M
Total Assets -- -- $283.8M $218.4M $179.2M
Current Liabilities -- -- $32.9M $32.4M $46.8M
Total Liabilities -- -- $155.9M $146.5M $163.7M
Total Equity -- -- $127.9M $71.8M $15.5M
Total Debt -- -- $79.1M $85.3M $91.5M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$71.1M -$46.4M -$34.6M -$8.3M $819K
Cash From Investing -$108.2M $18.4M $59.6M $7.7M $10.4M
Cash From Financing $229.2M -$5.9M -$5.1M -$756K -$243K
Free Cash Flow -$75.5M -$52.1M -$37.5M -$9.2M $1.2M
TOI
Sector
Market Cap
$22.6M
$47.1M
Price % of 52-Week High
12.2%
48%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-84.35%
-33.14%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $0.31
200-day SMA
Sell
Level $0.53
Bollinger Bands (100)
Buy
Level 0.22 - 0.34
Chaikin Money Flow
Sell
Level -45.3M
20-day SMA
Buy
Level $0.25
Relative Strength Index (RSI14)
Buy
Level 59.74
ADX Line
Buy
Level 40.95
Williams %R
Neutral
Level -34.096
50-day SMA
Buy
Level $0.24
MACD (12, 26)
Buy
Level 0.03
25-day Aroon Oscillator
Buy
Level 72
On Balance Volume
Sell
Level -15.1M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.5876)
Sell
CA Score (Annual)
Level (-1.924)
Buy
Beneish M-Score (Annual)
Level (-3.5313)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.1995)
Sell
Piotroski F Score (Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.

Stock Forecast FAQ

In the current month, TOI has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TOI average analyst price target in the past 3 months is --.

  • Where Will The Oncology Institute Stock Be In 1 Year?

    According to analysts, the consensus estimate is that The Oncology Institute share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About The Oncology Institute?

    Analysts are divided on their view about The Oncology Institute share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that The Oncology Institute is a Sell and believe this share price will drop from its current level to --.

  • What Is The Oncology Institute's Price Target?

    The price target for The Oncology Institute over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is TOI A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for The Oncology Institute is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of TOI?

    You can purchase shares of The Oncology Institute via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase The Oncology Institute shares.

  • What Is The The Oncology Institute Share Price Today?

    The Oncology Institute was last trading at $0.31 per share. This represents the most recent stock quote for The Oncology Institute. Yesterday, The Oncology Institute closed at $0.30 per share.

  • How To Buy The Oncology Institute Stock Online?

    In order to purchase The Oncology Institute stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Uber Stock Recover?
Will Uber Stock Recover?

Shares of Uber Technologies (NYSE:UBER) have had a rough few…

Is ARK Next Generation Internet ETF a Good Investment?
Is ARK Next Generation Internet ETF a Good Investment?

The ARK Next Generation Internet ETF looks like a pretty…

Why Is Marvell Stock Up?
Why Is Marvell Stock Up?

Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…

Stock Ideas

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Sell
44
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
1
IONQ alert for Jan 10

IonQ [IONQ] is up 7.07% over the past day.

Sell
47
CEG alert for Jan 10

Constellation Energy [CEG] is up 25.15% over the past day.

Sell
8
CRNX alert for Jan 10

Crinetics Pharmaceuticals [CRNX] is down 16.31% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock